World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
39869
World Ranking
8532
National Ranking
16

Overview

Chong-Jen Yu is affiliated with National Taiwan University in Taiwan, focusing primarily on medical research. Their work spans several interconnected fields within medicine, including pulmonary and respiratory medicine, oncology, infectious diseases, epidemiology, and surgery.

The scientist's research topics cover a variety of areas related to lung health and cancer, as well as infectious diseases and chronic conditions. Key topics include:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Diagnosis and Treatment
  • Tuberculosis Research and Epidemiology
  • Lung Cancer Research Studies
  • Mycobacterium Research and Diagnosis
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Cancer Immunotherapy and Biomarkers

Chong-Jen Yu has contributed extensively to the medical literature, with 448 publications categorized under medicine. Within that body of work, subfields with significant contributions include pulmonary and respiratory medicine (172 publications), oncology (64 publications), infectious diseases (49 publications), epidemiology (45 publications), and surgery (27 publications).

Frequent publication venues for the scientist include:

  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Journal of the Formosan Medical Association
  • SLEEP
  • Journal of Microbiology Immunology and Infection

Among recent papers, notable examples are:

  • Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer (2020), published in New England Journal of Medicine
  • Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia (2020), published in Journal of the American Society of Nephrology
  • Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial (2023), published in Journal of Clinical Oncology
  • Risk Factors for Mortality in 244 Older Adults With COVID-19 in Wuhan, China: A Retrospective Study (2020), published in Journal of the American Geriatrics Society
  • Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer (2021), published in Annals of Oncology

Frequent co-authors collaborating with Chong-Jen Yu include:

  • Jin-Yuan Shih
  • Jung-Yien Chien
  • Hao-Chien Wang
  • Chao-Chi Ho
  • Jann-Yuan Wang

Best Publications

  • MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

    James Bean;Cameron Brennan;Jin-Yuan Shih;Gregory Riely

  • Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

    Yi-Long Wu;Masahiro Tsuboi;Jie He;Thomas John

  • First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

    Jean-Charles Soria;Daniel S W Tan;Rita Chiari;Yi-Long Wu

  • Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

    James C.H. Yang;Lecia V. Sequist;Sarayut Lucien Geater;Chun Ming Tsai

  • MicroRNA Signature Predicts Survival and Relapse in Lung Cancer

    Sung Liang Yu;Hsuan Yu Chen;Hsuan Yu Chen;Gee Chen Chang;Chih Yi Chen

  • Value of sonography in determining the nature of pleural effusion: analysis of 320 cases.

    Pan-Chyr Yang;Kwen-Tay Luh;Dun-Bing Chang;Huey-Dong Wu

  • Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

    Tony S.K. Mok;Yi-Long Wu;Jin Soo Lee;Chong-Jen Yu

  • Mycobacterium abscessus Complex Infections in Humans.

    Meng-Rui Lee;Wang-Huei Sheng;Chien-Ching Hung;Chong-Jen Yu

  • Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

    Jenn-Yu Wu;Chong-Jen Yu;Yeun-Chung Chang;Chih-Hsin Yang

  • Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis.

    Jung-Yien Chien;Jih-Shuin Jerng;Chong-Jen Yu;Pan-Chyr Yang

  • Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells

    Ying-Chih Liu;Hsin-Yung Yen;Chien-Yu Chen;Chein-Hung Chen

  • Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

    Yi Long Wu;Jin Soo Lee;Sumitra Thongprasert;Chong Jen Yu

  • Pulmonary Sequelae in Convalescent Patients after Severe Acute Respiratory Syndrome: Evaluation with Thin-Section CT

    Yeun-Chung Chang;Chong-Jen Yu;Shan-Chwen Chang;Jeffrey R Galvin

  • Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.

    Jenn-Yu Wu;Shang-Gin Wu;Chih-Hsin Yang;Chien-Hung Gow

  • Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia.

    Qing Lan;Chao A. Hsiung;Keitaro Matsuo;Yun Chul Hong

  • Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy

    Chih-Hsin Yang;Chong-Jen Yu;Jin-Yuan Shih;Yeun-Chung Chang

  • Vascular Endothelial Growth Factor 189 mRNA Isoform Expression Specifically Correlates With Tumor Angiogenesis, Patient Survival, and Postoperative Relapse in Non–Small-Cell Lung Cancer

    Ang Yuan;Chong-Jen Yu;Sow-Hsong Kuo;Wen-Jone Chen

  • Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma.

    Jin Yuan Shih;Meng Feng Tsai;Tzu Hua Chang;Yih Leong Chang

  • Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

    C.-H. Gow;Y.-L. Chang;Y.-C. Hsu;M.-F. Tsai

  • Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome.

    Jung-Yien Chien;Po-Ren Hsueh;Wern-Cherng Cheng;Chong-Jen Yu

Frequent Co-Authors

Pan-Chyr Yang
Pan-Chyr Yang National Taiwan University
Po-Ren Hsueh
Po-Ren Hsueh China Medical University
Kwen-Tay Luh
Kwen-Tay Luh National Taiwan University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital
Wu Chou Su
Wu Chou Su National Cheng Kung University
Tony Mok
Tony Mok Chinese University of Hong Kong
Jianjun Liu
Jianjun Liu Genome Institute of Singapore
Meredith Yeager
Meredith Yeager Hood College
Chien-Jen Chen
Chien-Jen Chen Academia Sinica

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always mean becoming a doctor. The healthcare industry offers a range of educational pathways, including flexible online options that cater to different interests and backgrounds.

For those interested in nursing, you can find the easiest bsn program to get into or consider a nursing school that don't require teas, making admission more accessible to a wider range of applicants. These routes let students begin their nursing careers faster and with less stress during the application process.

If you prefer administrative or non-clinical roles, consider enrolling in one of the best medical billing and coding schools online. These programs prepare you for vital roles in healthcare administration, where demand continues to grow.

Aspiring healthcare leaders may also explore online health administration programs for accelerated degrees. This pathway is ideal if you want to impact patient care at a systems level, manage teams, and oversee hospital operations.

Best Scientists Citing Chong-Jen Yu

Trending Scientists

Recently Published Articles